Literature DB >> 25003491

The potential role of antigen spread in immunotherapy for prostate cancer.

Charles G Drake1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25003491      PMCID： PMC4876693     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  3 in total

1.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

2.  A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.

Authors:  Nancy J Nesslinger; Alvin Ng; Kwong-Yok Tsang; Theresa Ferrara; Jeffrey Schlom; James L Gulley; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2010-06-18       Impact factor: 12.531

3.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
  3 in total
  3 in total

Review 1.  Immunotherapy of Prostate Cancer: Facts and Hopes.

Authors:  Marijo Bilusic; Ravi A Madan; James L Gulley
Journal:  Clin Cancer Res       Date:  2017-06-29       Impact factor: 12.531

Review 2.  Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.

Authors:  Catherine E Handy; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2017-12-20       Impact factor: 3.404

3.  Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens.

Authors:  Paula Jaime-Sanchez; Iratxe Uranga-Murillo; Nacho Aguilo; Sofia C Khouili; Maykel A Arias; David Sancho; Julian Pardo
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.